博思軟件(300525.SZ)完成註銷約28.88萬份股票期權
格隆匯11月4日丨博思軟件(300525.SZ)公佈,公司於2019年9月29日召開第三屆董事會第十九次會議和第三屆監事會第十五次會議,審議通過《關於註銷2018年股票期權激勵計劃部分股票期權的議案》,鑑於原20名激勵對象因個人原因離職,根據公司《2018年股票期權激勵計劃(草案修訂稿)》的相關規定,對20名不符合激勵條件的激勵對象已獲授但尚未行權的股票期權合計約28.88萬份予以註銷,佔公司總股本的0.14%。
經中國證券登記結算有限責任公司深圳分公司審核確認,上述約28.88萬份股票期權的註銷事宜已於2019年11月4日辦理完畢。此次註銷的股票期權尚未行權,註銷後不會對公司股本造成影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.